Seattle Genetics Inc
$
70.64
-1.1 (-1.53%)
| Volume: | 606,080 | Avg Vol (1m): | 695,053 |
| Market Cap $: | 11.40 Bil | Enterprise Value $: | 10.98 Bil |
| P/E (TTM): | 0.00 | P/B: | 8.65 |
| Earnings Power Value | -7.94 |
| Net Current Asset Value | 2.49 |
| Tangible Book | 4.6 |
| Projected FCF | -1.55 |
| Median P/S Value | 77.97 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 9/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt ranked
higher than
98.14%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
SGEN:
No Debt
Ranked among companies with meaningful Cash-To-Debt only.
| N/A |
| Equity-to-Asset | 0.83 |
Equity-to-Asset ranked
higher than
81.52%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
SGEN:
0.83
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.36, Med: 0.76, Max: 0.96
Current: 0.83
|
| Interest Coverage | No Debt |
Interest Coverage ranked
higher than
98.00%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
SGEN:
No Debt
Ranked among companies with meaningful Interest Coverage only.
| N/A |
| Piotroski F-Score | 3 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 24.19 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.46 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -24.57%
WACC 13.95%
| ||
Profitability & Growth : 4/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -30.99 |
Operating Margin ranked
higher than
59.97%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
SGEN:
-30.99
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -163.3, Med: -37.81, Max: -23.35
Current: -30.99
|
| Net Margin % | -17.53 |
Net Margin ranked
higher than
68.56%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
SGEN:
-17.53
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -160.41, Med: -33.76, Max: -17.53
Current: -17.53
|
| ROE % | -9.40 |
ROE ranked
higher than
73.91%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
SGEN:
-9.4
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -79.94, Med: -27.14, Max: -9.4
Current: -9.4
|
| ROA % | -8.05 |
ROA ranked
higher than
75.37%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
SGEN:
-8.05
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -40.26, Med: -16.99, Max: -8.05
Current: -8.05
|
| ROC (Joel Greenblatt) % | -137.57 |
ROC (Joel Greenblatt) ranked
higher than
63.51%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
SGEN:
-137.57
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -903.49, Med: -253.26, Max: -137.57
Current: -137.57
|
| 3-Year Total Revenue Growth Rate | 24.80 |
3-Year Revenue Growth Rate ranked
higher than
69.59%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
SGEN:
16.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 7.7, Med: 28.65, Max: 148.1
Current: 16.8
|
| 3-Year Total EBITDA Growth Rate | -30.00 |
3-Year EBITDA Growth Rate ranked
lower than
80.05%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
SGEN:
-21.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: -31.6, Med: -4.25, Max: 30.1
Current: -21.7
|
| 3-Year EPS w/o NRI Growth Rate | -14.90 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
68.28%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
SGEN:
-14.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -27.9, Med: -3.6, Max: 34
Current: -14.9
|
» SGEN's 30-Y Financials
Financials (Next Earnings Date: 2019-07-26)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:SGEN
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325414   SIC : 2836 |
| Compare | OCSE:GEN HKSE:02269 HKSE:01177 NAS:IONS NAS:SAGE NAS:SRPT OCSE:NZYM B NAS:JAZZ XBRU:UCB HKSE:06160 NAS:TECH NAS:ALNY SZSE:000661 NAS:NBIX NAS:MRNA NAS:BLUE XAMS:GLPG NAS:BMRN NAS:EXEL NAS:ASND |
| Traded in other countries | SGT.Germany |
| Address | 21823 - 30th Drive South East, Building 3, Bothell, WA, USA, 98021 |
| Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 8.65 |
PB Ratio ranked
lower than
75.26%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
SGEN:
8.65
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 4.23, Med: 9.83, Max: 35.99
Current: 8.65
|
| PS Ratio | 16.03 |
PS Ratio ranked
lower than
60.74%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
SGEN:
16.03
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 10.06, Med: 17.68, Max: 45.33
Current: 16.03
|
| EV-to-EBIT | -49.95 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
SGEN:
-49.95
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -102.6, Med: -38.55, Max: -4.7
Current: -49.95
|
| EV-to-EBITDA | -56.80 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
SGEN:
-56.8
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -120.2, Med: -43.4, Max: -4.9
Current: -56.8
|
| EV-to-Revenue | 15.47 |
EV-to-Revenue ranked
lower than
56.68%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
SGEN:
15.47
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 7.4, Med: 16, Max: 40.4
Current: 15.47
|
| Current Ratio | 3.27 |
Current Ratio ranked
lower than
55.31%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
SGEN:
3.27
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 2.65, Med: 4.95, Max: 30.03
Current: 3.27
|
| Quick Ratio | 2.95 |
Quick Ratio ranked
lower than
55.96%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
SGEN:
2.95
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 2.29, Med: 4.62, Max: 30.03
Current: 2.95
|
| Days Inventory | 298.22 |
Days Inventory ranked
lower than
89.19%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
SGEN:
298.22
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 234.02, Med: 514.46, Max: 639.76
Current: 298.22
|
| Days Sales Outstanding | 80.77 |
Days Sales Outstanding ranked
lower than
73.20%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
SGEN:
80.77
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 40, Med: 61.03, Max: 562.77
Current: 80.77
|
| Days Payable | 170.80 |
Days Payable ranked
lower than
100.00%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
SGEN:
170.8
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 170.8, Med: 224.03, Max: 1833.79
Current: 170.8
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -4.70 |
3-Year Share Buyback Rate ranked
higher than
75.50%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
SGEN:
-4.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -113.5, Med: -11.05, Max: -2.2
Current: -4.7
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 15.36 |
Price-to-Tangible-Book ranked
lower than
80.87%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
SGEN:
15.36
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.78, Med: 8.29, Max: 33.75
Current: 15.36
|
| Price-to-Median-PS-Value | 0.91 |
Price-to-Median-PS-Value ranked
lower than
58.85%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
SGEN:
0.91
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.59, Med: 1.15, Max: 100
Current: 0.91
|
| Earnings Yield (Joel Greenblatt) % | -2.00 |
Earnings Yield (Greenblatt) ranked
higher than
69.66%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
SGEN:
-2
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -21.4, Med: -2.6, Max: -1
Current: -2
|
More Statistics
| Revenue (TTM) (Mil) $ | 709.31 |
| EPS (TTM) $ | -0.78 |
| Beta | 1.99 |
| Volatility % | 51.63 |
| 52-Week Range $ | 50.71 - 84.37 |
| Shares Outstanding (Mil) | 161.31 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 3 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |